BioCentury
ARTICLE | Clinical News

Axsome continues ascent with Phase III success in depression

December 17, 2019 1:14 AM UTC
Updated on Dec 17, 2019 at 2:39 AM UTC

With its depression therapy meeting in Phase III and plans to submit an NDA next year, Axsome has more than quadrupled its market cap since October, when it received a bump from a Phase II readout of a competing depression candidate also thought to work via NMDA receptor antagonism.

Axsome Therapeutics Inc. (NASDAQ:AXSM) gained $33.01 (71%) to $79.90 Monday for a gain of $1.1 billion in market cap after reporting AXS-05, a combination of dextromethorphan and bupropion, met the primary endpoint in the Phase III GEMINI trial to treat moderate to severe major depressive disorder (MDD). It plans to submit an NDA in 2H20...

BCIQ Company Profiles

Axsome Therapeutics Inc.

BCIQ Target Profiles

NMDA receptor